Effects of aminosalicylates
on thiopurine Smethyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
It can be concluded that the determination of TPMT phenotype in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by aminosalicylates
and cannot be used to investigate and/or predict the risk of thiopurine-induced toxicity potentially resulting from concomitant therapy with thiopurine and aminosalicylate
The mainstay of maintenance therapy is topical aminosalicylate
, combined with an oral salicylate if the topical alone is inadequate, said Dr.
Initiated patient enrollment in a Phase IIIb clinical study with UCERIS to evaluate whether there is an incremental benefit in remission rate when UCERIS 9 mg is added to current oral aminosalicylate
(5-ASA) therapy for patients with mild to moderate active ulcerative colitis not adequately controlled on background 5-ASA therapy.
Santarus) announced the completion of enrollment in the CONTRIBUTE clinical study, which is designed to evaluate the incremental benefit of adding UCERIS (budesonide) extended release 9mg tablets to oral aminosalicylate
(5-ASA) therapy for the induction of clinical remission in adult patients with active, mild to moderate ulcerative colitis.
NASDAQ: SNTS) today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS[TM] (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate
(5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
Active UC should be treated initially with systemic aminosalicylate
drugs (such as sulfasalazine, olsalazine, balsalazide, and mesalamine) or with corticosteroids.
The study enrolled 299 patients whose Crohn's disease had not responded to treatment with an aminosalicylate
, steroids, or immunomodulator drugs.
Sulfa-free [Asacol] aminosalicylate
typically associated with fewer [Pentasa] adverse effects than sulfasalazine.
TABLE 39 AMINOSALICYLATE
THERAPIES FOR INFLAMMATORY BOWEL DISEASE 70
Antibiotics metronidazole Antibiotics are usually second-line agents, used when the response to an aminosalicylate
There you also find individual revenue predictions to 2025 for five submarkets at world level: - Biologics - Aminosalicylates
- Antibiotics - Corticosteroids - Immunomodulators.